Overview

Methotrexate in the Treatment of Axial Spondyloarthritis

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the efficacy of oral methotrexate for the treatment of active axial spondyloarthritis (early ankylosing spondylitis or spondyloarthritis with sacroiliitis). Efficacy will be measured by reduction in the signs and symptoms of active spondyloarthritis including effects on back pain and stiffness, range of motion in the spine, physical function, quality of life and incidence of arthritis, enthesitis and anterior uveitis.
Phase:
Phase 4
Details
Lead Sponsor:
Rheumatism Foundation Hospital
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Methotrexate